Don’t reinvent the wheel — adapt it. Locate before you correct, because where a failure appears isn’t necessarily where it gets fixed.
- Closing The Gap Between Modeling And GMP Predictive Control
- Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
- What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
- How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
- Can Peptide Mapping Predict Intact Antibody PTM Distributions?
- The EU Overhauls Pharma Laws: What You Need To Know
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
GUEST COLUMNISTS
-
Closing The Gap Between Modeling And GMP Predictive Control
Predictive control offers opportunities to improve process consistency, reduce variability, and respond to changing manufacturing conditions before they cause deviations.
-
Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
-
How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
Europe's glass manufacturers, including those making pharmaceutical lab glassware, have experienced a series of energy shocks. Many have adopted sustainability practices.
-
Can Peptide Mapping Predict Intact Antibody PTM Distributions?
Peptide mapping quantifies modification at individual sites, but the same site-level results can correspond to different distributions across intact molecules.
-
The EU Overhauls Pharma Laws: What You Need To Know
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
BIOSIMILAR WHITE PAPERS
-
Perfusion Cell Line Development For Intensified Processes
The biopharmaceutical industry is transforming by shifting to continuous and intensified upstream bioprocesses, which are driven by evolving demands. Discover the key goals and innovations shaping this transition for modern healthcare.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling1/9/2026
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
Process Analytical Technology In The ADC Bioconjugation Process4/23/2025
Integrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
-
Process Intensification And Other Ways To Adapt To Changing Needs7/20/2026
As biologics manufacturing evolves, gain insight into why productivity depends on smarter investments, flexible production strategies, and supplier support that can address shifting modalities.
-
Ready To Demystify Organoids?7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
The Latest Updates For Sterile Filtration And Single-Use Assemblies11/5/2026
Revised sterile manufacturing rules shift attention from isolated compliance tasks to evidence that sterility holds across filtration, aseptic connections, single-use systems, and suppliers.
BIOSIMILAR APP NOTES & CASE STUDIES
- Multi-Column Chromatography For Efficient Polishing Purification
- Mild pH Protein A Purification Step With A Mild Elution Resin
- Controlling mAb Aggregates In Chromatography Process Development
- Selecting A Platform Filter For High Concentration mAbs
- Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Biocon Gets U.S. FDA Approval For Pebrilzo (pertuzumab-qcay) Injection, A Biosimilar To Perjeta, Expanding Its Oncology Portfolio
- Celltrion to Present New Analyses of OMLYCLO® (omalizumab-igec) In Chronic Spontaneous Urticaria At ACAAI 2026
- Lupin Announces European Launch Of Biosimilar Ranibizumab
- Sandoz launches Ranluspec (ranibizumab) In Europe, Providing An Affordable Treatment Option For Patients With Retinal Diseases
- Henlius Presents New Studies At ISPOR Europe 2026 To Advance Treatment Value Assessment And Global Access
- AEON Biopharma Submits IND For Comparative Pharmacodynamic Study Of ABP-450
- New Biosimilar For Patients With Certain HER2-Positive Breast Cancer Is Approved By Anvisa
- GlycoNex Announces Japanese Regulatory Submission For Denosumab Biosimilar SPD8
NEWSLETTER ARCHIVE
- 11.12.26 -- 5 Steps To Achieving Your Biosimilar Milestones On Time
- 11.05.26 -- 7 Decisions To Make Before MES Configuration
- 10.29.26 -- How Indian Biosimilar Companies Are Poised To Succeed
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
